Quick answers
- What is Brilinta?
- Brilinta is a brand name of Ticagrelor, a prescription medicine. The FDA NDC Directory lists 4 Brilinta products in 2 strengths and forms.
- Who makes Brilinta?
- Astrazeneca holds the FDA application for Brilinta (NDA022433, approved July 20, 2011). 2 other companies (repackagers or distributors) also list Brilinta products.
- Is there a generic or store brand of Brilinta?
- Yes. The FDA NDC Directory lists 29 other products with the same active ingredients, strength and form as a Brilinta product, 29 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Brilinta?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 2 Brilinta strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Brilinta been recalled?
- FDA enforcement reports list 2 recalls of Brilinta products; the newest started March 15, 2021. A recall usually concerns specific lots, not every product.
What Brilinta is
Each Brilinta product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Ticagrelor · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| ticagrelor 60 mg tablet (oral) | Brilinta | 12 products, 12 companies | DailyMed |
| ticagrelor 90 mg tablet (oral) | Brilinta | 17 products, 16 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Ticagrelor →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA022433 | Astrazeneca | July 20, 2011 | 4 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ticagrelor 60 mg tablet | Brand: Brilinta | $7.42 per tablet Generic of the same strength and form: $0.2624 per tablet |
| ticagrelor 90 mg tablet | Brand: Brilinta | $7.42 per tablet Generic of the same strength and form: $0.2429 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Brilinta
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Brilinta products.
- AstraZeneca Pharmaceuticals LP2 products
- Cardinal Health 107, LLC1 product
- Aphena Pharma Solutions - Tennessee, LLC1 product
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0433-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Brilinta ticagrelar tablets 60 mg 60 tablets Rx only NDC 0186-0776-60 Mfd. for: AstraZeneca LP, Wilmington, DE 19850 — Cardinal Health Inc.
-
May 25, 2017 · Class I · Terminated · D-0958-2017
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08. — AstraZeneca Pharmaceuticals, LP
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.